Recent studies tried to assess the behavior of hybrid peptides such as GLP1 linked with glucagon, GIP or any other intestinal peptide, in an effort to lower blood glucose levels in T2DM patients [73]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.